What is the Staph ID/R Blood Culture Panel from Great Basin?
Great Basin’s Staph ID/R Blood Culture Panel is an Identification (ID) and Resistance (R) Panel for Staphylococcus aureus (including MRSA), Staphylococcus species, Staphylococcus lugdunensis, and mecA gene that confers antibiotic resistance when found in any of these organisms. Patients with bacteria in their bloodstream are often the sickest and most expensive patients in the hospital. The Great Basin Staph ID/R Blood Culture Panel provides results in hours as opposed to days using only traditional methods to aid in the proper treatment protocols for patients.
What are the key advantages of Great Basin’s Staph ID/R Blood Culture Panel?
- Results in under 2 hours means clinicians have answers they need to treat with appropriate therapy.
- Detects S. aureus (MRSA and MSSA) and the mecA gene (methicillin resistance), which will inform the accurate selection of antibiotic therapy for the patient.
- Detects CoNS contaminants, which clears the patient for step-down therapy (off Vancomycin) and discharge.
- Identifies S. lugdunensis, a CoNS that is always considered a true pathogen requiring antibiotic therapy.
- One-step, true sample-to-result – pipette sample into the test cartridge, insert panel into the analyzer and press “start.” Our system is simple to use, easy to learn and can be run 24/7.
- Staph ID/R provides results in HOURS as opposed to DAYS using only traditional methods.
Our customers were asking for it. They wanted a Staph ID/R assay that could run on our easy to use, simple platform. What we ended up developing was a test unlike anything on the market in that it detects CoNS, which may not require antibiotic therapy. Thus, our Staph ID/R panel could contribute to reducing the number of unnecessary antibiotic prescriptions written to patients, saving hospitals valuable resources and reducing costs.
Is there a strong need for this panel in the diagnostics market?
There is not another sample-to-result panel targeted to gram positive blood cultures that will only distinguish MRSA from MSSA, or confirm if it’s a non-pathogenic CoNS contaminant. This is a simple, streamlined, cost-effective and fast way to get clinicians answers they need to provide patients with the best treatment. As hospitals adopt formal antimicrobial stewardship programs, they will need diagnostic solutions to develop better prescription protocols. The Great Basin molecular diagnostic platform, including the Staph ID/R panel, could be used to help curb the over-prescription of antibiotics and lower hospitals costs by discharging people who don’t need to be in the hospital. (The CDC estimates that roughly 47 million prescriptions written for antibiotics in the US annually are unnecessary.)
Why should microbiology labs be interested in the Staph ID/R panel?
Staph ID/R is very easy to run, with a simple workflow, so it can be a 24/7 STAT test. It costs less than competitive panels, which don’t offer the same clinically relevant answers, and there is no charge for instrumentation, which allows more hospitals – including Critical Access Hospitals that may not normally have access to sophisticated diagnostic solutions – to offer molecular diagnostics without capital expense. Great Basin is committed to customer success and offers training and unlimited customer service without additional fees or contracts to help get labs up and running quickly and providing actionable results to better treat patients.
How can hospitals specifically benefit from the Staph ID/R panel?
The biggest benefits of rapid diagnostic testing are significant cost benefits to hospitals and shorter stays for patients. One study found that associated patient costs from rapid intervention went from $45,709 to $26,162, while mean length of stay went from ~11 days to ~9 days . Staph ID/R provides results in hours as opposed to days using only traditional methods.
How does the Staph ID/R panel fit within antimicrobial stewardship?
The CDC estimates that there are 47 million unnecessary prescriptions for antibiotics written each year in the U.S. These scripts have and will continue to lead to the development of superbugs that are resistant to available antibiotics. The CDC estimates that over 10 million Americans will die from untreatable superbugs by 2050. The Staph ID/R panel is the only rapid blood culture product currently on the market that only distinguishes CoNS from MRSA/MSSA, enabling hospitals to correctly administer antibiotics when there is a true infection versus administering empirically. Rapid blood culture testing has been shown to improve time to optimal therapy leading to reduced antibiotic resistance, reduced costs and improved patient outcomes.
What should clinicians, pharmacists and microbiology lab directors and supervisors know about this panel?
The barriers to implementing rapid blood culture diagnostics have traditionally included capital costs, service contract costs, high reagent cost, and the need for greater ease of use. Great Basin’s platform removes these barriers, enabling every lab of any size the ability to offer Standard of Care for their patients.